AIM ImmunoTech Files Proxy Statement

Ticker: AIM · Form: DEFA14A · Filed: Nov 22, 2024 · CIK: 946644

Sentiment: neutral

Topics: proxy-statement, filing-update, investor-relations

TL;DR

AIM ImmunoTech filed proxy docs Nov 22, presented to Institut. No fee.

AI Summary

AIM ImmunoTech Inc. filed a DEFA14A on November 22, 2024, indicating it presented an investor presentation to Institut. The filing is a definitive additional material, and no fee was required for this filing. The company, formerly known as Hemispherx Biopharma Inc., is incorporated in Delaware and based in Ocala, Florida.

Why It Matters

This filing provides shareholders with important information regarding company communications and potentially upcoming decisions, impacting their voting rights and investment outlook.

Risk Assessment

Risk Level: low — This filing is a routine proxy statement and does not contain information that suggests immediate or significant financial risk.

Key Players & Entities

FAQ

What type of filing is this DEFA14A for AIM ImmunoTech Inc.?

This filing is a Definitive Additional Material, as indicated by the checkmark next to 'Definitive Additional Materials' and the filing date of November 22, 2024.

Was there a fee associated with this filing?

No, the filing explicitly states 'No fee required' with a checkmark next to it.

What is the primary business of AIM ImmunoTech Inc.?

AIM ImmunoTech Inc. is in the business of Biological Products (No Diagnostic Substances), with SIC code 2836.

When was AIM ImmunoTech Inc. formerly known as?

AIM ImmunoTech Inc. was formerly known as HEMISPHERX BIOPHARMA INC, with a date of name change on 19950614.

What specific event is mentioned in relation to the filing date?

On November 22, 2024, AIM ImmunoTech Inc. presented an investor presentation to Institut.

Filing Stats: 662 words · 3 min read · ~2 pages · Grade level 14.9 · Accepted 2024-11-22 17:26:36

Filing Documents

From the Filing

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under § 240.14a-12 AIM ImmunoTech Inc. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 On November 22, 2024, AIM ImmunoTech Inc. (the “Company”) presented the following investor presentation to Institutional Shareholder Services Inc., a copy of which is attached hereto as Exhibit 1. The Company also intends to use the presentation for discussions with its stockholders in connection with the Company’s 2024 Annual Meeting of Stockholders (the “Annual Meeting”). Forward Looking Statements The presentation attached contains forward-looking “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date does not guarantee that Ampligen will be approved as a therapy for endometriosis or ovarian cancer. The Company urges investors to consider specifically the various risk factors identified in its most recent Annual Report on Form 10-K, and any risk factors or cautionary statements included in any subsequent Quarterly Report on Form 10-Q or Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission (the “SEC”). You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of the presentation attached hereto. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking or circumstances that occur after the date hereof. Important Additional Information The Company, its directors and executive officers, Peter W. Rodino, III and Robert Dickey, IV, are deemed to be “participants” (as defined in Section 14(a) of the Securities Exchange Act of 1934, as amended) in the solicitation of proxies from the Company’s stockholders in connection with the Annual Meeting. The Company filed its definitive proxy statement (the “Definitive Proxy Statement”) and a WHITE universal proxy card with the SEC on November 4, 2024 in connection with such solicitation of proxies from the Company’s stockholders. STOCKHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ SUCH DEFINITIVE PROXY STATEMENT, ACCOMPANYING WHITE UNIVERSAL PROXY CARD AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY CONTAIN IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING. The Definitive Proxy Statement contains information regarding the identity of the participants, and their direct and indirect interests, by security holdings or otherwise, in the Company’s securities and can be found in the section titled “Principal Stockholders” of the Definitive Proxy Statement and available here . Information regarding subsequent changes to their holdings of the Company’s securities can be found in the SEC filings on Forms 3, 4, and 5, which are available on the Company’s website available here or through the SEC’s website at www.sec.gov. Stockholders will be able to obtain the Definitive Proxy Statement, any amendments or supplements thereto and other documents filed by the Company with the SEC at no charge at the SEC’s website at www.sec.gov. Copies will also be available at no charge at the Company’s website at https://aimimmuno.com/sec-filings/. Exhibit 1

View Full Filing

View this DEFA14A filing on SEC EDGAR

View on Read The Filing